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ABSTRACT
This paper reviews the methods, beneﬁts and challenges
associated with the adoption and translation of
computational ﬂuid dynamics (CFD) modelling within
cardiovascular medicine. CFD, a specialist area of
mathematics and a branch of ﬂuid mechanics, is used
routinely in a diverse range of safety-critical engineering
systems, which increasingly is being applied to the
cardiovascular system. By facilitating rapid, economical,
low-risk prototyping, CFD modelling has already
revolutionised research and development of devices such
as stents, valve prostheses, and ventricular assist devices.
Combined with cardiovascular imaging, CFD simulation
enables detailed characterisation of complex
physiological pressure and ﬂow ﬁelds and the
computation of metrics which cannot be directly
measured, for example, wall shear stress. CFD models
are now being translated into clinical tools for physicians
to use across the spectrum of coronary, valvular,
congenital, myocardial and peripheral vascular diseases.
CFD modelling is apposite for minimally-invasive patient
assessment. Patient-speciﬁc (incorporating data unique
to the individual) and multi-scale (combining models of
different length- and time-scales) modelling enables
individualised risk prediction and virtual treatment
planning. This represents a signiﬁcant departure from
traditional dependence upon registry-based, population-
averaged data. Model integration is progressively moving
towards ‘digital patient’ or ‘virtual physiological human’
representations. When combined with population-scale
numerical models, these models have the potential to
reduce the cost, time and risk associated with clinical
trials. The adoption of CFD modelling signals a new era
in cardiovascular medicine. While potentially highly
beneﬁcial, a number of academic and commercial groups
are addressing the associated methodological, regulatory,
education- and service-related challenges.
INTRODUCTION
Computational ﬂuid dynamics (CFD) is a well-
established tool used in engineering, in many areas
of which it has become the primary method for
design and analysis. Bioengineers have adopted
CFD to study complex physiological ﬂows and
have demonstrated their potential.1 There is
increasing interest in applying these methods in car-
diovascular medicine.2 3 CFD-based techniques are
being used to build complex computer representa-
tions (in silico models) of the cardiovascular system
in health and disease. CFD modelling is a new ﬁeld
within cardiovascular medicine, enhancing diagnos-
tic assessment, device design and clinical trials.
It can predict physiological responses to interven-
tion and compute previously unmeasurable haemo-
dynamic parameters.4 As CFD modelling continues
to translate into clinical tools, it is important that
clinicians understand the principles, beneﬁts and
limitations of these techniques. This article explores
these topics using state-of-the-art examples in key
clinical areas, highlighting applications likely to
impact clinical practice within the next 5 years
(table 1).
WHAT IS CFD?
CFD is a specialist area of mathematics and a
branch of ﬂuid mechanics. It is used in the design of
many safety-critical systems, including aircraft and
vehicles, by solving differential equations to simu-
late ﬂuid ﬂow. A glossary of uesful terms is provided
in table 2.
For incompressible ﬂows, almost all CFD analyses
solve the Navier-Stokes and continuity equations
which govern ﬂuid motion. These equations are
non-linear, partial differential equations based upon
the principle of conservation of mass and momen-
tum. Simpliﬁcation of these equations yields famil-
iar formulae (eg, those of Bernoulli and Poiseuille);
but for complex geometries analytical solutions are
not possible, so specialised software applications
(CFD solvers) calculate approximate numerical
solutions. Non-linearity, due to convective ﬂuid
acceleration, makes this challenging, especially in
three dimensional (3D) models; so CFD analyses
require signiﬁcant computational power and time.
CFD MODEL COMPLEXITY
The applications reviewed in this paper focus on
3D CFD analyses of local regions of the vasculature
because this is where promising applications are
beginning to translate and impact upon clinical
medicine. There is a long history of simpliﬁcation
of the governing equations to lower spatial dimen-
sions. Table 3 summarises the relationship between
these approaches and provides clinical examples of
their use.
2D analyses typically assume symmetry of the
solution about the central axis, 1D models capture
variation of the solution along the axial direction
only, and 0D representations lump the behaviour of
vascular regions into a model with no spatial dimen-
sions, hence the term ‘lumped-parameter models’.
Due to the breadth of the literature covering appli-
cation of these techniques to cardiovascular haemo-
dynamics, the interested reader is referred to recent
reviews of the state-of-the-art.45 46
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Table 1 Summary of CFD modelling applications in cardiovascular medicine
Area Clinical applications Data and evidence Potential clinical impact Limitations and challenges References
Coronary artery
disease and
physiology
Models based upon
coronary angiography (CT
/invasive) to compute
physiological coronary lesion
significance less invasively
Multiple trials
demonstrating broadly good
agreement between
standard and CFD-derived
FFR (vFFR). Lesion
significance established in
∼80–90%
Widened access to the
benefits of physiological
lesion assessment; vFFR lacks
the practical limitations that
restrict use of the invasive
technique. Virtual stenting
enables planning and
selection of optimal
treatment strategy
Accurate vessel reconstruction
and patient-specific tuning of
the model boundary
conditions (especially those of
myocardial resistance)
5 6 7 8
Valve prostheses Evaluation and optimisation
of prosthetic valve design
from a haemodynamic
perspective
Included in the design
dossier given to RA for
approval before use in
humans. Third party,
comparative studies are in
engineering literature
CFD modelling enables the
best design, yielding the
optimal haemodynamics and
lowest achievable risk of
design-related thrombosis
and thromboembolism
Dependence upon validity of
models to interpret fluid
stresses in terms of
thrombogenic/haemolytic
potential. Primarily relates to
mechanical valves. Tissue
valve leaflets remain
challenging to model
9 10 11
Native valve
haemodynamics in
health and disease
Non-invasive computation
and quantification of
trans-valvular pressure drop
and regurgitant fraction
from CT imaging
Accurate 3D simulations in
patient-specific models with
valves in open and closed
states to predict
transvalvular dynamics in
diseased states
Improved objective
assessment and surveillance
of valve disease from
non-invasive imaging data
Requires high quality 3D
images of valve orifice—not
routinely generated.
Balancing the requirement for
complex dynamic simulation
(FSI) vs simpler models (valve
open/closed)
12 13
Aortic aneurysm Provides quantitative
haemodynamic data for
non-invasive imaging to
emphasise the significance
of findings. Virtual therapy
simulation/predictions
No published outcome
trials, only single centre
experiences and small
cohorts using different
boundary condition and
computational methods
To better predict aneurysm
progression and risk of
rupture. Prediction of
putative therapeutic effects.
Individualised care and
reduction in costs for
unnecessary follow-up
imaging and visits
Impact of low image contrast
structures of aortic aneurysm
(eg, wall, thrombus) as well
as wall motion needs to be
further assessed. CFD alone is
probably limited and needs to
be complemented by, for
example, FSI
3 14 15 16
Aortic dissection Pathophysiological
conditions in true and false
lumen computed from
non-invasive boundary
conditions (CT and MRI
+PC). Effects of virtual
therapy.
No published outcome
trials, only single centre
experiences and small
cohorts using different
boundary conditions and
computational methods
Computed pressure and flow
conditions used to guide
(semi-) invasive therapeutic
procedure decisions.
Physiological effects of
therapies can be simulated
and better predicted
Significant early and late
re-modelling of the dissected
wall. Entry, re-entry and
communication channels
create a complex
computational scenario.
CFD alone might be limited.
A potential role for FSI
17 18 19
Stent design Prediction of WSS and
related metrics that
influence endothelial
function and NH due to
stent-induced
haemodynamic disturbance
Turbulent or disturbed
laminar flow reduces WSS
stimulating adverse vessel
remodelling. NH
preferentially accumulates in
these regions
Not possible to measure
arterial WSS in vivo,
especially in the vicinity of
stent struts post-PCI.
Modelling provides detailed
analysis of flow, and the
influence of stent design
through patient-specific
reconstructions, enabling the
optimal stent design to be
achieved
High resolution imaging,
vessel reconstruction and
boundary conditions are
challenging. CFD simulations
demand fine computational
meshes and time-resolved
pulsatility. Run-times are
long, even with high
performance computing
20 21 22 23 24 25 26 27
Cerebral aneurysm Prediction of
intra-aneurysmal flow,
stasis, jet impingement and
WSS from MRI and CT
cerebral angiography data
Published data on
association between WSS,
aneurysm initiation, growth,
and potentially rupture
Detailed, individualised
haemodynamic analysis with
potential for risk prediction.
Impact of putative treatments
on local haemodynamics
evaluated in silico
Difficulty interpreting complex
and detailed WSS results.
Understanding how results
translate to rupture risk.
Validation of rupture
predictions—a rare event
4 28 29
Pulmonary
hypertension (PH)
Greater insights into
complex PH physiology.
Increasing interest in
non-invasive diagnosis and
monitoring of response to
treatment
Models based on MR flows
demonstrated to
differentiate between
healthy volunteers and to
stratify PH subcategories
Imaging-based modelling of
pulmonary haemodynamics
can reduce the requirement
for right heart
catheterisation. Models show
association between reduced
WSS and invasive PH metrics.
PH subtype characteristics
simulated to understand the
structural changes
contributing to increased PAP
Spatial resolution of imaging
and segmentation protocols.
The use of a pressure
surrogate measure. The
presence of many outlets
requiring many measurements
to tune the outflow boundary
conditions
30 31 32 33
Arterial wall shear
stress (WSS)
WSS mapping,
cross-referenced with
An abnormal WSS pattern
has been correlated with
Ultimate understanding of
the development and
A detailed vascular geometry
is essential for an accurate
20 21 22 25
Continued
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MODEL CONSTRUCTION
CFD model construction and solution can be described in seven
stages (ﬁgure 1):
1. Clinical imaging
A range of medical imaging modalities can be used, including
ultrasound, CT, MRI and X-ray angiography. Imaging must
provide sufﬁcient anatomical and physiological detail, in an
appropriate format and quality, to enable segmentation and data
extraction.49
2. Segmentation and reconstruction
Segmentation methods convert medical images to in silico
geometries which deﬁne the physical bounds of the model
region of interest. If images are acquired over a cardiac cycle,
anatomical motion can be tracked over segmented regions.50 51
3. Discretisation
Spatial discretisation, or ‘meshing’, divides the geometry into
a number of discrete volumetric elements or cells. Temporal dis-
cretisation divides the solution into discrete time steps. The
accuracy and numerical stability of the analysis are inﬂuenced by
both spatial and temporal reﬁnement. The fabrication of the
mesh, and the level of mesh reﬁnement, are inﬂuenced by
case- and context-speciﬁc factors. The mesh and timestep (ie,
spatio-temporal discretisation) must be reﬁned enough to
capture the important haemodynamic behaviour of the mod-
elled compartment (the ﬁnal solution should be independent of
mesh parameters), but without excessive reﬁnement because this
impacts negatively on computational resource and solution time
(see online supplementary table S1).
4. Boundary conditions
Because it is impossible to discretise the entire cardiovascular
system, the region to be analysed will have at least one inlet and
one outlet. To enable CFD analysis, the physiological conditions
at the wall and inlet/outlet boundaries must be speciﬁed.
Boundary conditions are a set of applied physiological para-
meters (which may vary over time) that deﬁne the physical con-
ditions at the inlets, outlets and walls. They may be based on
patient-speciﬁc data, population data, physical models or
assumptions.39
Table 1 Continued
Area Clinical applications Data and evidence Potential clinical impact Limitations and challenges References
vascular disease phenotype,
is contributing to the
understanding of cellular
biology
vascular diseases, including
atherosclerosis, aneurysm
and post-stent NH
progression of
atherosclerosis. WSS map
combined with multi-scale
modelling may inform clinical
practice, such as the site of
rupture in aneurysm, and
severity of in-stent restenosis.
WSS map. Acquisition of
patient specific boundary
conditions remains clinically
challenging.
Heart failure Models based upon CT and
MR help compute
haemodynamics and the
spatio-temporal distributions
of pressure and myocardial
stress/strain
CFD/FSI models replicate
realistic pathophysiology in
models of health and
disease (eg, HFREF, HFPEF,
HCM, DCM, and RWMA
post-MI)
Additional haemodynamic
data potentially enables early
diagnosis and stratifies
disease phenotypes and
severities. Characterising
complex vortex flows
identifies areas of flow
stagnation and thrombus risk
Resolution of imaging and
reconstruction (representing
trabeculae and papillary
muscles). Tuning with realistic
boundary conditions.
Requirement for FSI in many
models
2 34 35 36 37 38 39 40 41
CRT Coupled electro-mechanical
models of the ventricle
incorporating CFD
(multi-physics models) used
to investigate heart function
Published reports of
accurate patient-specific
haemodynamic simulations
with sufficient detail to
optimise CRT before
surgical intervention
Improved selection of CRT
responders. Simulation and
selection of optimal tuning of
device settings and lead
placement on an individual
case basis
Uncertainties and
assumptions regarding
boundary conditions and the
range of clinical
measurements required for
parameterisation. Mesh
generation, prolonged
computation times
VADs Generic optimisation of
pump design.
Patient-specific models can
aid implantation strategy
and tuning of output
according to patient
physiology
Published models describing
haemodynamic influences of
catheter placement and
minimisation of adverse
haemodynamic effects
Pump tuning to ensure
periodic opening and closing
of AV, preventing leaflet
fusion. Personalised catheter
placement planning
(prediction and avoidance
stasis and thrombus
formation)
Post-implantation imaging
artefact limits modelling.
Optimising performance
requires the balance of
multiple competing factors.
As for all cardiac
electromechanical models,
selection of appropriate
patient specific parameters is
difficult due to sparsity of
data
Congenital heart
disease
CFD simulates
haemodynamics which are
complex and hard to predict
in the context of a diverse
and heterogeneous range of
disease phenotypes
Range of models described,
including reduced order, 3D
CFD, FSI and multiscale,
particularly in the context of
univentricular circulation,
aortic and pulmonary
malformations
Modelling enables greater
understanding of systemic
and regional haemodynamics
and the prediction of
response to putative surgical
or device-based treatments
which often involve
significant modifications to
the circulatory tree
Acquisition and application of
model parameters and
boundary conditions from
patient and literature data.
The ultimate personalisation
challenge
42 43 44
AV, aortic valve; CFD, computational fluid dynamics; CRT, cardiac resynchronisation therapy; CT (A), CT (angiography); DCM, dilated cardiomyopathy; FSI, fluid solid interaction; HCM,
hypertrophic cardiomyopathy; HFPEF, heart failure with preserved EF; HFREF, heart failure with reduced EF; MI, myocardial infarction; NH, neointimal hyperplasia; PAP, pulmonary artery
pressure; PC, phase-contrast; PCI, percutaneous coronary intervention; RA, regulatory authority; RWMA, regional wall motion abnormality; (v)FFR; (virtual) fractional flow reserve; VAD,
ventricular assist device; WSS, wall shear stress.
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5. Simulation
A computer ﬁle deﬁning the physical parameters of the model
is written. In addition to the geometric, discretisation and
boundary data, this ﬁle must deﬁne properties including: blood
density and viscosity (ie, the ﬂuid model), the initial conditions
of the system (eg, whether the ﬂuid is initially static or moving),
time discretisation information (time step size and numerical
approximation schemes), and the desired output data (eg,
number of cardiac cycles to be simulated). This information
allows the CFD solver to solve the Navier-Stokes and continuity
equations, proceeding incrementally towards a ﬁnal solution
(‘convergence’). A typical 3D cardiovascular simulation involves
>1 million elements run over several cardiac cycles, each
divided into hundreds or thousands of individual time-steps.
Millions of non-linear partial differential equations are solved
simultaneously, and repeatedly, over all elements, at all time-
steps. 3D CFD modelling is therefore time-consuming and
computationally demanding.
6. Post-processing
Typically, the CFD solver produces the pressure and velocity
ﬁeld over all elements at each time-step. Only a small propor-
tion of these data are of interest to the operator, so some post-
processing is required to extract and display relevant data.18
7. Validation
It is important that modelled results are validated against an
acceptable standard. Commonly, this involves comparison with
either values measured within an in vitro phantom or acquired
during in vivo assessment.4 Validation generates conﬁdence in
the accuracy and reliability of a CFD model.
THE WORKFLOW
Collectively, the steps outlined above are known as a workﬂow
or toolchain (see ﬁgure 1 and online supplementary video).
Although there are many specialised software applications facili-
tating the construction and operation of CFD-based workﬂows,
considerable skill and experience are required at each stage
(especially steps 3–5) to ensure reliability of results.49
ADVANCED BOUNDARY CONDITIONS
Rather than specifying pressure or ﬂow at a boundary, an add-
itional, lower-order model may be coupled to the 3D solver to
generate more realistic conditions proximal and distal to the
simulation domain (see table 1 and ﬁgure 2). This method of
modelling is efﬁcient, because it allows detailed analysis in the
3D region without wasting high temporal and spatial reﬁnement
on regions beyond this. In some cases the model representing
the distal boundary also provides proximal boundary condition.
These closed-loop models, or system models, require very
careful tuning.52
ASSUMPTIONS
Many CFD models assume that the segmented region has rigid
walls. Although untrue in the cardiovascular system, this
Table 2 CFD—a glossary of selected useful terminology
Analytical solution Relatively simple models can be described by solving a number of equations using mathematical analysis techniques such as calculus
or trigonometry. The solution is analytical because an exact solution can be obtained through algebraic manipulation of the equations
(cf. numerical solution).
Bernoulli equation:
Pþ ð1=2ÞrV2 þ rgh ¼ constant
Rearranged and simplified:
DP ¼ ð1=2ÞrðV22  V21Þ
The Bernoulli equation relates blood pressure (P) and flow velocity (V). The total energy of flowing blood comprises hydrostatic (P),
kinetic ((1/2)ρV2) and potential (ρgh where ρ is fluid density, g is gravity and h is height) energies, the sum of which is conserved.
Therefore, an increase in flow velocity must be accompanied by a decrease in pressure, and vice versa. Gravitational effects (ρgh) are
usually neglected in a supine vessel. The simplified and rearranged equation is used routinely to calculate transvalvular pressure
gradients from flow velocity. The Bernoulli equation ignores energy loss due to viscous friction (see Poiseuille equation) and
turbulence, and assumes steady flow.
Boundary conditions A set of parameters or relationships which describe the physiological conditions (haemodynamic or structural) acting at the boundaries
of a modelled segment, representing the interaction of the model with its distal compartments.
Discretisation To divide into discrete elements or time periods.
Electrical analogue An electrical circuit design used to represent a compartment of the circulation, using, for example, ‘voltages’ (pressures), ‘current’
(flow) and resistors. They lack spatial dimensions and are therefore also referred to as dimensionless or ‘zero-D’ (0D) models.
In silico ‘Represented or simulated in a computer’, comparable to in vivo and in vitro.
Multi-scale model A model which integrates models of different length- and or time-scales.
Newtonian and non-Newtonian
fluid
As blood is a suspension, non-Newtonian behaviour is particularly important within the capillaries where the size of (solid) blood cells
is large relative to vessel calibre, resulting in a non-linear relationship between shear-stress and viscosity. In larger blood vessels
Newtonian fluid behaviour is often assumed whereby viscosity is constant, independent of the shear-stress acting on the fluid.
Numerical solution In more complex models the mathematics becomes too complicated for analytical techniques and numerical techniques are used
instead. Rather than generating an exact solution, the result is an approximation, albeit within very close bounds under certain
circumstances. Typically, iterative methods are employed to produce a solution to the equations that converges around the true values.
Used to resolve complicated, non-linear, transient (time-varying) analyses for example, 3D-CFD models.
Poiseuille equation:
Q ¼ DPpr
4
8mL
Rearranged:
DP ¼ 8mLQ
pr4
The Poiseuille equation describes blood flow (Q), along a vessel in relation to viscosity (μ), vessel geometry (length (L) and radius (r))
and the driving pressure gradient (ΔP). According to Poiseuille, flow is strongly dependent upon vessel radius (fourth power).
Poisuille’s equation considers viscous (frictional) energy losses.
Segmentation The process by which relevant structures in medical images are identified, isolated and converted into computer representations.
Windkessel German for ‘air-chamber’. Windkessel models are relatively simple zero-D models used to represent the resistive and compliant
properties of the arterial vasculature.
Workflow A sequence of applications (computational tools) which are executed sequentially to manipulate medical data to build a model and
perform computational analyses. Typically this involves medical imaging, segmentation, discretisation, CFD simulation and
post-processing, that is, from clinical imaging to results. Sometimes referred to as a tool-chain.
CFD, computational fluid dynamics.
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approximation is acceptable for some applications.53 54 Vessel
compliance allows blood to be stored during systole and
released during diastole. At the system level this results in a
ﬁnite speed of pressure wave transmission and tends to reduce
the peak pressures associated with the inertial acceleration of
the blood. Compliance tends to reduce shear stresses because
the vessels are slightly larger when peak ﬂow occurs. It is pos-
sible to model deformation of the wall, due to cardiac and
respiratory variation, in response to change in pressure using
ﬂuid-solid interaction (FSI) models. These are far more complex
to solve, boundary conditions are a challenge, and many wall
parameters remain unknown, which increases the number of
assumptions. Furthermore, it is yet to be established for which
applications a full FSI approach improves accuracy. An example
of the increased computational cost of FSI is reported by Brown
et al54 where 3D transient (time-varying) analysis of the aorta
required 145 h (FSI) compared with 6.6 h (CFD). An alternative
is to impose wall movement derived from imaging data (eg,
gated MRI). There are exciting developments in the use of data
assimilation techniques in which sparse clinical data, for
example, from 4D imaging, are integrated with the analysis
process so that material properties of tissues in individual
patients are recovered as the simulation progresses.55 In biomed-
ical workﬂows it is assumed the boundaries of the ﬂuid geom-
etry are smooth, yet medical images may not generate smooth
surfaces due to poor resolution or imaging artefacts. Instead,
structures may be smoothed in silico after segmentation.
Typically, cardiovascular simulations assume blood behaves as an
incompressible ﬂuid. Although blood exhibits non-Newtonian
behaviour (see glossary in table 2), which must be simulated for
ﬂow in small capillaries, in larger vessels these effects are often
neglected and a Newtonian ﬂuid model is assumed.
BENEFITS OF CARDIOVASCULAR CFD MODELLING
CFD modelling enables investigation of pressure and ﬂow ﬁelds
at a temporal and spatial resolution unachievable by any clinical
methodology. Post-processing provides additional data, generat-
ing new insights into physiology and disease processes. For
example, it is difﬁcult, and invasive, to measure arterial wall
shear stress (WSS), a key factor in the development of athero-
sclerosis and in-stent restenosis, whereas CFD models can
compute WSS and map its spatial distribution.20 21 Such work
has established the link between haemodynamic disturbance and
atherogenesis and has explained the preferential deposition of
atherosclerotic plaque at arterial bends and bifurcation
regions.22 CFD modelling has been central to our current
understanding of the effects of WSS on endothelial homeostasis:
laminar, non-disturbed blood ﬂow is associated with increased
WSS which inhibits unnecessary endothelial cell activation;
whereas turbulent or disturbed blood ﬂow reduces WSS which
stimulates adverse vessel remodelling. A complex series of
WSS-related signalling pathways and interactions underlie this
phenomenon. Before these pathways can be exploited to gener-
ate anti-atherosclerotic therapies their complexity needs to be
Table 3 A summary of the various orders of CFD modelling applied to the cardiovascular system
Model Figure CFD solution Description/examples
Typical solution
time†
0D * No spatial dimension. Physiological
variables such as pressure (P), flow (Q)
and resistance (R) are assumed
spatially uniform within the model,
varying only as a function of time (t),
eg,
PðtÞ ¼ QðtÞ  RðtÞ
Solved with ordinary differential (0D
NS) equations
Lump together distributed physiological systems
into a single description. They describe the global
behaviour of the modelled segment. The 0D
Windkessel model (pictured) is often used to
represent the compliant and resistive nature of
the arterial circulation. 0D models are frequently
used to model components of the cardiovascular
system or to improve boundary conditions for 3D
models of arterial, ventricular or venous
pathophysiology.5 47
Immediate solution
1D Physiological variables are solved as a
function of a single spatial variable,
typically length (x), eg,
Pðx;tÞ ¼ Qðx;tÞ  Rðx;tÞ
Solved with partial differential (1D NS)
equations
Used to represent wave propagation
characteristics and wave reflection. 1D models
may also be used to provide boundary conditions
for higher order models in order to increase
refinement of the solution, especially where the
effects of wave reflection are significant.45 46
S (static)
Min (transient)
2D Physiological variables are solved as a
function of two spatial variables,
typically length and distance from
centreline (r) eg,
Pðx;r;tÞ ¼ Qðx;r;tÞ  Rðx;r;tÞ
Solved with axisymmetric NS
equations
Able to resolve the solution in 2D. Used less
often now than previously due to ready
availability of improved computer processing and
3D solvers. Examples include the simulation of
para-prosthetic valve haemolysis and
improvement of the assessment of the proximal
flow convergence zone in the clinical evaluation
of regurgitant valve disease.48
3D Physiological variables are solved as a
function of all three spatial variables,
including the angle around the
centreline axis (θ) eg,
Pðx;r;u;tÞ ¼ Qðx;r;u;tÞ  Rðx;r;u;tÞ
Solved with full 3-D NS equations
Full 3D CFD can resolve the physiological solution
in all dimensions including time. Examples are
more widely reviewed in the main body of the
text.
Order of minutes for
steady- state
Order of hours or
days for transient
*Hydro-electrical analogue diagrams are often used to describe physiological components such as resistance, pressure (voltage), compliance (capacitance), and flow (current).
†Solution times vary according to complexity of the model and the mathematical solution. The times presented are approximate and are based on a model of coronary physiology.5
CFD, computational fluid dynamics; NS, Navier-Stokes; 0D, zero dimensional; 1D, one dimensional; 2D, two dimensional; 3D, three dimensional.
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better understood. Integrated multiscale CFD models provide a
powerful tool to combine analysis of ﬂuid mechanics and cellu-
lar response.23 Recently, the effect of disturbed WSS in stented
vessels has been modelled to investigate the inﬂuence on both
endothelial function and neointimal hyperplasia, which
preferentially accumulates at regions of low and disturbed WSS
(ﬁgure 3).26 Such models can be used to develop stents which
minimise the risk of in-stent restenosis and thrombosis.24 25
Device design
In silico methods allow rapid prototyping, with reduced risk to
humans, so a priority for the medical devices industry is to
replace expensive and time-consuming in vivo and in vitro
experimentation with in silico testing. In recognition of this, the
US Food and Drug Administration (FDA) issued draft guidance
in 2014 on the use of modelling to support regulatory submis-
sions.56 An example is the signiﬁcant role which CFD plays in
Figure 1 Examples of aortic (A) and
coronary (B) in silico computational
ﬂuid dynamics (CFD) workﬂows. (A)
The aorta is identiﬁed from thoracic
MRI (a), segmented and reconstructed
(central image). A volumetric mesh is
fabricated to ﬁt the patient-speciﬁc
geometry, shown in detail in panel (b).
Accurate ﬂow measurements are
extracted from phase-contrast MRI
data to inform the boundary conditions
applied for CFD simulation, such as the
inlet (c). The results are
post-processed, details of the ﬂow
ﬁeld are shown in panel (d). 0D
models are coupled at the outlets so
physiologically feasible ﬂow-pressure
relationships are computed at the
outlets (e). These can be validated
against other measurements, which in
a preclinical scenario may be invasive.
(B) (and accompanying online video) A
coronary angiogram (a) is segmented
(b) and reconstructed into a 3D in
silico model. A surface and volumetric
are fabricated to ﬁt the patient-speciﬁc
geometry (c). Physiological parameters
such as pressure and ﬂow are used to
inform the boundary conditions
applied for CFD simulation (d). The
results (here pressure and ﬂow) are
post-processed and useful
physiological data are extracted (e). In
the preclinical, research setting
simulated results are validated against
an appropriate standard, for example,
invasively measured values (f ).
(Additional information for video
legend): VIRTUheart is an academic
project at the University of Shefﬁeld
funded by research grants (see
virtuheart.com).
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design optimisation of mechanical heart valves.11 While com-
parison of major ﬂow features captured in vitro with predictions
from CFD shows good agreement, simulation delivers 3D infor-
mation at much higher resolution within critical regions (eg, the
hinges) than ﬂow visualisation, giving invaluable insight into
design-related thrombogenic potential.10 Comprehensive simula-
tion of heart valve mechanics, including the separation of the
upstream and downstream ﬂuid regions at closure and the struc-
tural instability and snap-through dynamics of tissue valves,
remain computationally challenging but achievable.9 13
CFD has been used in the optimisation of several commercial
ventricular assist devices (VADs), investigating potential
thrombogenicity by highlighting design-related regions of stasis
and device characteristics resulting in high shear stress.41 A tool
for optimising thromboresistance has been recently demon-
strated in a comparative study of two continuous ﬂow VADs,
which combines experimental and numerical simulation.40 57
Numerical models can also contribute to the process of VAD
implantation, informing the choice of catheter implantation
site.39
In the context of stent design, the greatest emphasis has been
on modelling the mechanical integrity of the stent structure
during and after deployment. However, CFD provides a valu-
able tool to assess the resulting haemodynamics within the
stented lesion.26 This, in turn, has been associated with the bio-
logical response of the vessel wall and the development of
restenosis.27
Diagnostic tools and personalised medicine
Computing intravascular physiology, with the aim of minimising
invasive instrumentation, is of major interest. A prime example
is fractional ﬂow reserve (FFR), an index of physiological (cor-
onary atherosclerosis) lesion signiﬁcance, measured with a
pressure-sensitive angioplasty guidewire. FFR-guided therapy
improves patient outcomes, reduces stent insertions, and
reduces costs, yet it is used in <10% of cases due to a host of
procedural and operator related factors.58 Several groups
propose models for computing ‘virtual’ FFR from angiography
to provide the beneﬁts of physiological assessment without the
practical drawbacks which limit the invasive technique (see
online supplementary ﬁgure S1).5 6 7 59 The VIRTU-1 trial
demonstrated the effectiveness of CFD-derived FFR using inva-
sive angiography (diagnostic accuracy 97% vs invasive FFR).5
More recently, the HeartFlow-NXT trial demonstrated the per-
formance of virtual FFR using CT coronary angiography (sensi-
tivity 86%, speciﬁcity 79% vs invasive FFR).6 Both models
offer a less invasive approach, neither requires hyperaemic ﬂow
induction nor the passage of an intracoronary wire, and taken
together could offer the beneﬁts of FFR to all patients being
assessed for coronary artery disease (CAD). CTFFR (HeartFlow
Inc) is now FDA approved for use as a class II Coronary
Physiologic Simulation Software Device.60
Recent in vitro work combining CFD, colour Doppler and
simulated Doppler images demonstrates the potential to reduce
Doppler inter-user variability and inform interpretation of
complex regurgitant ﬂow ﬁelds in valvular heart disease.61 In
silico models of the right heart and pulmonary arteries using
phase-contrast MRI capture anatomical and ﬂow velocity data
to simulate pulmonary artery physiology.62 It is hoped that
these models will soon deliver a diagnosis of pulmonary hyper-
tension without invasive catheterisation.31 Added value may
come from wave analysis of these models to discriminate
between the key aetiological sub-groups of pulmonary
hypertension.30
Treatment decisions are often based upon the ‘gold standard’
of randomised controlled trials. Everyday clinical practice,
however, requires tailored treatment for individual patients.
CFD modelling offers a patient-speciﬁc approach to manage-
ment, in which an individual’s unique anatomy and physiology
are used to deﬁne the model. The impact of alternative interven-
tional strategies can be compared and a personalised, optimised
strategy selected.63 Patient-speciﬁc modelling will not diminish
the need for clinical trials but will allow the delivery of truly
objective, personalised management on a wide scale.
This approach is exempliﬁed in aortic aneurysm management,
where current simplistic guidelines use aneurysm diameter as
the arbiter of treatment. The @neurIST project addresses this,
and incorporates patient-speciﬁc anatomic, genomic and demo-
graphic data, with simulated ﬂow patterns (ﬁgure 4), to calculate
the risk of rupture.64 The optimal treatment of aortic type B
Figure 2 A patient-speciﬁc 3D computational ﬂuid dynamics model
of an aorta. Patient-speciﬁc pressure is the proximal boundary
condition. Each outlet (distal boundary) is coupled to a
zero-dimensional model. The zero-dimensional models represent the
impedance (Z), resistance (R) and compliance/capacitance (C) of the
circulation distal to the boundaries. Output data from the 3D domain
provide input to the 0D model and vice versa. The algebraically coded
0D models compute parameters which are returned back to
dynamically inform the 3D simulation. An alternative would be to
couple a 1D wave transmission model at the outlets which may provide
higher ﬁdelity simulation results, especially in the aorta where the
physiology is inﬂuenced by wave reﬂections.
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dissections remains controversial. Thoracic endovascular aortic
repair (TEVAR) carries a risk of spinal ischaemia, and multiple
communicating channels between true and false lumens confer a
risk of proximal rupture if only the primary entry is closed.
Therefore, graft length is balanced against the risk of paraplegia.
In this context, CFD modelling provides individualised risk
stratiﬁcation and optimised treatment delivery (ﬁgure 5).65 18
Similar simulations are useful in the context of abdominal aortic
aneurysm.66 67
FULL SYSTEM MODELS: THE VIRTUAL PHYSIOLOGICAL
HUMAN
There is increasing interest in integrating multiple physiological
models into comprehensive system models to simulate the
impact of various conditions, pathologies and treatments across
multiple organ systems. While this is ambitious, large, inter-
national, collaborative research projects under the umbrella of
the Virtual Physiological Human (VPH) reﬂect the seriousness,
legitimacy and rationale underlying this long-term vision.68 Full
system models offer the possibility of understanding, holistically,
the impact of cardiovascular disease upon individual patients.
IN SILICO TRIALS
In silico techniques can simulate measures of safety, accuracy,
and efﬁcacy of interventions, both pharmacological and mech-
anical, in large cohorts of virtual patient models which represent
naturally occurring physiological and pathological variability.
This minimises the time, cost, and risk associated with clinical
Figure 3 A computational ﬂuid dynamics (CFD) model demonstrating the correlation between wall shear stress (WSS) and restenosis in coronary
artery disease. (A) Structural modelling of stent insertion in porcine coronary arteries reconstructed from micro-CT, and stent–artery coupling
obtained after arterial recoil. (B) Comparison between the in vivo histological images (left) and corresponding sections from the structural simulation
(right) demonstrating excellent agreement. (C) Results of the CFD simulations in terms of the spatial distribution of WSS magnitude over the arterial
wall. (D) The correlation between areas characterised by low WSS (orange lines) and in-stent restenosis after 14 days. The CFD simulation of WSS
has identiﬁed areas of reduced shear and restenosis with excellent agreement. Figure reproduced from Morlacchi et al26 with kind permission from
Springer Science and Business Media.
Figure 4 Computational ﬂuid dynamics (CFD) model of an intracranial berry aneurysm from the @neurist project. Panel (A) demonstrates the
reconstructed surface mesh. Panels (B) and (C) demonstrate the CFD simulated pressure (B) and wall shear stress (C) acting upon the aneurysm wall,
which may be useful in predicting risk of rupture on a patient-speciﬁc basis.
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trials. The Avicenna project leverages signiﬁcant commercial
interest and engagement to develop a ‘roadmap’ describing the
route by which multi-scale in silico techniques can achieve
this.69
CHALLENGES AND LIMITATIONS
CFD models in medicine have traditionally been used by two
user groups: industrial medical device developers, in rapid,
low-cost, device prototyping; and academics, to investigate car-
diovascular physiology and compute parameters that cannot
otherwise be obtained. Both groups construct models which are
typically complex, involve multiple ﬁnely-tuned geometric,
haemodynamic and material parameters and require long com-
putation times. In contrast, clinicians are a third, emerging user
group, who require rapid results with adequate accuracy.
Model accuracy is determined by model design and quality of
input data. For CFD applications it is unclear how detailed the
clinical data needs to be in terms of geometry (segmented from
medical images) and parameterisation (variability described by
the model and the tuning of patient-speciﬁc boundary condi-
tions). Continuing improvements in imaging, image-registration
and segmentation algorithms will augment accuracy.50 Model
parameterisation is more challenging, because it requires
detailed knowledge of physiological metrics in the proximal and
distal circulations which may be inaccessible and variable in
health and in disease, for example, microcirculatory resistance is
a major determinant of coronary blood ﬂow. Further under-
standing of the relative importance of physiological parameters
is required to determine those which are most inﬂuential, and
those which can be assumed or averaged.70 This allows
Figure 5 Segmentation, reconstruction and 3D simulation of a chronic type B aortic dissection with true and false lumen in systole (top row) and
diastole (bottom row). The primary entry point (top arrow) is close to the left subclavian artery. Two more communications (‘re-entries’) are seen
distally. Computational ﬂuid dynamics simulation allows the ﬂow through each re-entry point to be studied separately in order to predict response
to intervention. During systole simulation demonstrates high blood ﬂow velocity through the primary entry point. However, simulation predicts
signiﬁcant ﬂow through the ﬁrst re-entry point in systole, and even higher during diastole, thus demonstrating that closure of the primary entry
point alone will not be sufﬁcient to induce false lumen thrombosis and avoid further expansion. Reproduced with permission from Chen et al,
2013.18
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unnecessary model complexity to be simpliﬁed, balancing com-
puting speed against accuracy.54 A second challenge is the devel-
opment of relevant industry standards. In the European Union
and USA, diagnostic software is regulated via CE marking and
FDA directives, respectively; but there are no industry standards
governing accuracy, reliability or validation. The FDA is addres-
sing this through benchmarking initiatives, in the same way that
aviation authorities adopted computer-aided design over trad-
itional physical testing.71 Third, large volumes of clinical data,
of value for model development and validation, are stored in
hospital systems. Access is variable and restrictive; although the
VPH-Share project demonstrates how anonymised patient-
speciﬁc data and in silico models can be shared securely.72
Access to such data supports model validation against long-term
outcomes which may expedite clinical translation. Fourth, CFD
modelling can be perceived as a ‘disruptive technology’, and a
threat, especially by manufacturers of traditional hardware.
Finally, the next generation of doctors will require training in in
silico systems, and understanding their principles, methodolo-
gies and limitations. Several initiatives are attempting to address
this, but in the longer term, in silico medicine may gain promin-
ence in medical curricula.68 73 74
FUTURE DIRECTIONS
In the context of device development, the major computational
modelling and technological challenges have already been
addressed and the beneﬁts of simulation are recognised by the
regulatory authorities. Sustained investment will enable engi-
neers to continue model reﬁnement and the development of
novel applications, speciﬁcally targeting increases in precision,
personalisation and speed. Beyond technological development,
and before these tools become established in routine clinical
practice, the most immediate need is to demonstrate equivalence
of in silico results relative to invasive measurements through
observational trials. Beyond this, efﬁcacy must be demonstrated
in large multicentre clinical trials. It is clear that these techni-
ques have the potential to change clinical practice. The beneﬁ-
ciaries will be patients, clinicians and healthcare providers.
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